Treatment Category Profile

Treatment Name:	everolimus	Known as: Also Known As:	Certican Afinitor
Treatment Type:	Multi-Targeted	Status:	FDA Approved (phase III)
Researchers evaluated whether treatment with the targeted therapy drug everolimus (Certican) could slow the growth and spread of renal cell carcinoma (a type of kidney cancer) when other targeted therapies, such as sunitinib (Sutent) and/or sorafenib (Nexavar), stopped working.

   Articles related to this Treatment

	1 Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors docguide.com Sep 15, 2010 2 New kidney cancer drug gets TGA tick Life Scientist Nov 19, 2009 3 Everolimus: in advanced renal cell carcinoma. DocGuide Oct 22, 2009 4 New Drug Helps Patients with Advanced Kidney Cancer Live Longer Cancer.Net May 16, 2008